{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:24:24Z","timestamp":1792301064954,"version":"4.4.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.autrev.2017.11.002","type":"journal-article","created":{"date-parts":[[2017,11,3]],"date-time":"2017-11-03T23:49:44Z","timestamp":1509752984000},"page":"4-10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Can we manage lupus nephritis without chronic corticosteroids administration?"],"prefix":"10.1016","volume":"17","author":[{"given":"Liz","family":"Lightstone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank L.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Larosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne M.","family":"Bargman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2017.11.002_bb0005","first-page":"75","article-title":"What happens after complete withdrawal of therapy in patients with lupus nephritis","volume":"31","author":"Moroni","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.12.011","article-title":"Comprehensive evaluation for the treatment of lupus nephritis","volume":"78","author":"Zampeli","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.11.002_bb0015","first-page":"233","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev"},{"key":"10.1016\/j.autrev.2017.11.002_bb0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.autrev.2010.11.009","article-title":"The kaleidoscope of glucorticoid effects on immune system","volume":"10","author":"Zen","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.11.002_bb0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/ard.62.11.1071","article-title":"Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus","volume":"62","author":"Doria","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/acr.21664","article-title":"American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis","volume":"64","author":"Hahn","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.11.002_bb0035","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/annrheumdis-2012-201940","article-title":"Joint European league against rheumatism and European renal association-European dialysis and transplant association (EULAR\/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis","volume":"71","author":"Bertsias","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0040","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1177\/0961203307087612","article-title":"Lupus: improving long-term prognosis","volume":"17","author":"Doria","year":"2008","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0045","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.autrev.2013.10.013","article-title":"Prednisone in lupus nephritis: how much is enough?","volume":"13","author":"Ruiz-Irastorza","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.11.002_bb0050","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12916-016-0673-8","article-title":"Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis","volume":"14","author":"Singh","year":"2016","journal-title":"BMC Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0055","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3899\/jrheum.080828","article-title":"Prednisone, lupus activity, and permanent organ damage","volume":"36","author":"Thamer","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0060","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1136\/annrheumdis-2015-207347","article-title":"Prolonged remission in Caucasian patients with SLE: prevalence and outcomes","volume":"74","author":"Zen","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0065","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/annrheumdis-2016-210154","article-title":"The effect of different durations of remission on damage accrual: results from a prospective monocentric cohort of Caucasian patients","volume":"76","author":"Zen","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0070","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/rheumatology\/kev311","article-title":"The frequency and outcome of lupus nephritis: results from an international inception cohort study","volume":"55","author":"Hanly","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.11.002_bb0075","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/art.39026","article-title":"Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the euro-lupus nephritis cohort","volume":"67","author":"Dall'Era","year":"2015","journal-title":"Arthritis Rheum (Hoboken, NJ)"},{"key":"10.1016\/j.autrev.2017.11.002_bb0080","first-page":"133","article-title":"The effect of cortisone in glomerulonephritis and the nephropathy of disseminated lupus erythematosus","volume":"37","author":"Heller","year":"1951","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0085","first-page":"259","article-title":"The effects of hormones and vitamins on rheumatoid arthritis with special reference to cortisone, hydrocortisone and corticotropin","volume":"23","author":"Hench","year":"1952","journal-title":"Int Z Vitaminforsch"},{"key":"10.1016\/j.autrev.2017.11.002_bb0090","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1681\/ASN.V871189","article-title":"The natural history of the renal manifestations of systemic lupus erythematosus. 1964","volume":"8","author":"Pollak","year":"1997","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0095","first-page":"308","article-title":"Systemic lupus erythematosus. The effect of corticotropin and adrenocorticoid therapy on survival rate","volume":"98","author":"Posnick","year":"1963","journal-title":"Calif Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0100","first-page":"405","article-title":"The effects of cortisone and adrenocorticotropic hormone (ACTH) on certain rheumatic diseases","volume":"72","author":"Boland","year":"1950","journal-title":"Calif Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1056\/NEJM198301273080403","article-title":"The long-term clinical course of systemic lupus erythematosus in end-stage renal disease","volume":"308","author":"Coplon","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0110","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/rheumatology\/ker410","article-title":"Glucocorticoid use and abuse in SLE","volume":"51","author":"Ruiz-Irastorza","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2017.11.002_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000066","article-title":"Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus-the Hopkins lupus cohort","volume":"2","author":"Al Sawah","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0120","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0125","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1177\/0961203313476155","article-title":"Minimising steroids in lupus nephritis\u2014will B cell depletion pave the way?","volume":"22","author":"Lightstone","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0130","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/01.tp.0000189716.50701.2d","article-title":"Five years of steroid sparing in renal transplantation with tacrolimus and mycophenolate mofetil","volume":"81","author":"Borrows","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.autrev.2017.11.002_bb0135","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1111\/j.1600-6143.2004.00583.x","article-title":"Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation","volume":"4","author":"Borrows","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2017.11.002_bb0140","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1191\/0961203302lu243oa","article-title":"Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications","volume":"11","author":"Badsha","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0145","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/ard.46.10.773","article-title":"Double blind controlled trial of methylprednisolone infusions in systemic lupus erythematosus using individualised outcome assessment","volume":"46","author":"Edwards","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0150","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.3899\/jrheum.120537","article-title":"Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study","volume":"39","author":"Fischer-Betz","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0155","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1177\/0961203311418269","article-title":"Efficacy and safety of enteric-coated mycophenolate sodium in combination with two glucocorticoid regimens for the treatment of active lupus nephritis","volume":"20","author":"Zeher","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0160","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0165","first-page":"61A","article-title":"SaO041 Prospective long term follow up of the Rituxilup steroid sparing regimen in lupus nephritis","volume":"25","author":"Porter","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0170","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1093\/ndt\/gfp336","article-title":"Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids","volume":"24","author":"Pepper","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.11.002_bb0175","first-page":"27","article-title":"Treating lupus nephritis with rituximab and Mycophenolate Mofetil (RituxiRescue regimen) without increasing maintenance oral steroids leads to sustained disease remission and steroid reduction","volume":"500A","author":"Pillay C Levy","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0180","author":"Inc. AP"},{"key":"10.1016\/j.autrev.2017.11.002_bb0185","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0190","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0195","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","article-title":"Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the lupus-cruces and lupus-Bordeaux cohorts","volume":"16","author":"Ruiz-Irastorza","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2017.11.002_bb0200","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJM197811232992102","article-title":"Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide","volume":"299","author":"Donadio","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0205","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJM198603063141004","article-title":"Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs","volume":"314","author":"Austin","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0210","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","author":"Group. KDIGO (KDIGO) GW","year":"2012","journal-title":"Kidney Int."},{"key":"10.1016\/j.autrev.2017.11.002_bb0215","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/1529-0131(200012)13:6<406::AID-ART11>3.0.CO;2-2","article-title":"Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient nonadherence","volume":"13","author":"Bruce","year":"2000","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.autrev.2017.11.002_bb0220","first-page":"1955","article-title":"Accrual of organ damage over time in patients with systemic lupus erythematosus","volume":"30","author":"Gladman","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0225","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/0140-6736(92)92292-N","article-title":"Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis","volume":"340","author":"Boumpas","year":"1992","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.autrev.2017.11.002_bb0230","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1002\/art.10461","article-title":"Immunosuppressive therapy in lupus nephritis: the euro-lupus nephritis trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide","volume":"46","author":"Houssiau","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1136\/ard.2008.102533","article-title":"The 10-year follow-up data of the euro-lupus nephritis trial comparing low-dose and high-dose intravenous cyclophosphamide","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0240","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0245","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMoa1014460","article-title":"Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis","volume":"365","author":"Dooley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0250","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1136\/ard.2010.131995","article-title":"Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN nephritis trial","volume":"69","author":"Houssiau","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0255","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2215\/CJN.02271205","article-title":"A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years","volume":"1","author":"Moroni","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0260","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1053\/j.ajkd.2016.07.026","article-title":"Membranous lupus nephritis: the same, but different","volume":"68","author":"Ward","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0265","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1177\/0961203315593169","article-title":"Colchicine: a simple and effective treatment for pericarditis in systemic lupus erythematosus? A report of 10 cases","volume":"24","author":"Morel","year":"2015","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0270","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1136\/annrheumdis-2014-206897","article-title":"Long-term follow-up of the MAINTAIN nephritis trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis","volume":"75","author":"Tamirou","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2017.11.002_bb0275","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0280","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1177\/0961203313483376","article-title":"Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis","volume":"22","author":"Davies","year":"2013","journal-title":"Lupus"},{"key":"10.1016\/j.autrev.2017.11.002_bb0285","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0290","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1002\/art.22505","article-title":"Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis","volume":"56","author":"Gunnarsson","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0295","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3899\/jrheum.130005","article-title":"Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment","volume":"41","author":"Touma","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0300","doi-asserted-by":"crossref","first-page":"622","DOI":"10.3899\/jrheum.140157","article-title":"Resolution of proteinuria in lupus nephritis: hurry up and wait","volume":"41","author":"Bargman","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2017.11.002_bb0305","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2011.08.002","article-title":"Membranous nephropathy in systemic lupus erythematosus: long-term outcome and prognostic factors of 103 patients","volume":"41","author":"Moroni","year":"2012","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0310","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaut.2016.06.006","article-title":"Lupus nephritis: when and how often to biopsy and what does it mean?","volume":"74","author":"Moroni","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.11.002_bb0315","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1002\/acr.20318","article-title":"Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French autoimmunity and rituximab registry","volume":"62","author":"Terrier","year":"2010","journal-title":"Arthritis Care Res."},{"issue":"Suppl. 11","key":"10.1016\/j.autrev.2017.11.002_bb0320","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/ndt\/17.suppl_11.28","article-title":"The malnutrition, inflammation, and atherosclerosis (MIA) syndrome \u2014 the heart of the matter","volume":"17","author":"Pecoits-Filho","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.autrev.2017.11.002_bb0325","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0002-9343(76)90431-9","article-title":"The bimodal mortality pattern of systemic lupus erythematosus","volume":"60","author":"Urowitz","year":"1976","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0330","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0335","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1002\/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I","article-title":"Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus","volume":"44","author":"Esdaile","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2017.11.002_bb0340","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa035471","article-title":"Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Roman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.11.002_bb0345","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jaut.2016.06.014","article-title":"Success and failure of biological treatment in systemic lupus erythematosus: a critical analysis","volume":"74","author":"Gatto","year":"2016","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2017.11.002_bb0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2016.08.007","article-title":"From old concerns to new advances and personalized medicine in lupus: the end of the tunnel is approaching","volume":"74","author":"Doria","year":"2016","journal-title":"J Autoimmun"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217302756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T10:50:51Z","timestamp":1659783051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217302756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":70,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1568997217302756"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.11.002","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we manage lupus nephritis without chronic corticosteroids administration?","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.11.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}